Literature DB >> 937081

Interferon therapy in Hodgkin's disease. A case report.

H Blomgren, K Cantell, B Johansson, C Lagergren, U Ringborg, H Strander.   

Abstract

The treatment of a case of Hodgkin's disease (lymphocyte predominance, stage IV B) with exogenous i.m. interferon therapy is described. B symptoms disappeared, diseased nodes and pulmonary infiltrations decreased in size, and laboratory values normalized. Clinical improvement was associated with increased mitogenic responsiveness of the patient's lymphocytes towards various stimuli in vitro. After almost half a year's treatment tumour progression and a decreased mitogenic response were again observed. Interferon treatment was then abandoned and combined cytostatic courses were instituted. Partial remission was achieved after 6 months of cytostatic therapy, i.e. 1 year after the start of treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 937081     DOI: 10.1111/j.0954-6820.1976.tb06776.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  15 in total

Review 1.  Antiviral agents: action and clinical use.

Authors:  T W Chang; D R Snydman
Journal:  Drugs       Date:  1979-11       Impact factor: 9.546

Review 2.  Interferons: anti-neoplastic drugs?

Authors:  H Strander
Journal:  Blut       Date:  1977-09-18

Review 3.  Does interferon cure cancer?

Authors:  K Sikora
Journal:  Br Med J       Date:  1980-09-27

Review 4.  Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.

Authors:  R B Pollard
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

5.  Clinical and immunological studies of human fibroblast interferon.

Authors:  K Ezaki; M Ogawa; K Okabe; K Abe; K Inoue; N Horikoshi; J Inagaki
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Interferon-induced differentiation of U937 cells. Comparison with other agents that promote differentiation of human myeloid or monocytelike cell lines.

Authors:  T Hattori; M Pack; P Bougnoux; Z L Chang; T Hoffman
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

7.  Aging in vitro and large-scale interferon production by 15 new strains of human diploid fibroblasts.

Authors:  J S Horoszewicz; S S Leong; M Ito; L Di Berardino; W A Carter
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

8.  Clinical effect of interferon in malignant brain tumours.

Authors:  M Nagai; T Arai
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

9.  Electrophoretically pure mouse interferon exerts multiple biologic effects.

Authors:  I Gresser; J De Maeyer-Guignard; M G Tovey; E De Maeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

10.  Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy.

Authors:  L Tentori; M P Fuggetta; S D'Atri; A Aquino; C Nunziata; M Roselli; P Ballatore; E Bonmassar; L De Vecchis
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.